TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02027194
Drug: Cure-Allergic Rhinitis Syrup
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered one bottle for two weeks to the participants twice
Study: NCT02027194
Drug: Yu-ping-fung San
Normalized name: Fung-A-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered one bottle for 2-week usage to the participants twice
Study: NCT02027194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
Study: NCT02470767
Drug: Direct Oral Anticoagulant (DOAC)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment pattern following the summary of product characteristics
Study: NCT03111732
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
Study: NCT03750669
Drug: AG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
Study: NCT03750669
Drug: mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
Study: NCT04679818
Drug: Routine opioid management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
Study: NCT03315559
Drug: [14C]-GSK2269557 IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
Study: NCT03315559
Drug: [14C]-GSK2269557 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
Study: NCT02767245
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine IV 100 mg/day
Study: NCT00328809
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone administered to ESRD patients at low dose
Study: NCT00775086
Drug: norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04062331
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
Study: NCT01472835
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used for analgesia and as a sedative
Study: NCT01098578
Drug: Floseal
Normalized name: Floseal Hemostatic Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received 1 syringe of Floseal as treatment for posterior epistaxis.
Study: NCT04002427
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
Study: NCT04002427
Drug: Inhaled dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single inhalation on one occasion.
Study: NCT01796444
Drug: Adjuvant Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
Study: NCT03358290
Drug: JTE-051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug tablets containing JTE-051
Study: NCT03358290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to the active drug tablets
Study: NCT00860964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, calcium 900mg/d, VitD200iu/d and exercise
Study: NCT00726804
Drug: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
Study: NCT01112267
Drug: Tramadol HCl/acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
Study: NCT01112267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
Study: NCT01112267
Drug: Tramadol HCl/acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
Study: NCT01112267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
Study: NCT03889795
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin oral pill will be taken daily in the evening.
Study: NCT01404325
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: centre specific CNI-based triple drug immunosuppression
Study: NCT00060385
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060385
Drug: EPOCH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060385
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00060385
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02733588
Drug: G-Pump™ (glucagon infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
Study: NCT03012945
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
Study: NCT03352206
Drug: 3 drug dose - IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study: NCT01204164
Drug: TG02 citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 citrate capsules given orally.
Study: NCT03593408
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered for sedation management per hospital protocol
Study: NCT04290676
Drug: DEXYCU (dexamethasone intraocular suspension) 9%.
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
Study: NCT00556712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT00284934
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00284934
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At a dose of at least 5 mg/day.
Study: NCT02885922
Drug: anti-diabetic drug
Normalized name: INVESTIGATIONAL ANTI-DIABETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on anti-diabetic drug in type 2 diabetic patients
Study: NCT00326495
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
Study: NCT01389284
Drug: Naproxen Sodium ER (BAYH6689)
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
Study: NCT01389284
Drug: Naproxen Sodium IR (Aleve, BAYH6689)
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
Study: NCT01389284
Drug: Naproxen Sodium ER Placebo
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
Study: NCT01389284
Drug: Naproxen Sodium IR Placebo
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
Study: NCT02216877
Drug: Mablet 360 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784927
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00422461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral, tablets, once daily, for 28 days
Study: NCT03548415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously.
Study: NCT01454063
Drug: OMS302
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT01454063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT05125627
Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Study: NCT03010865
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
Study: NCT03142451
Drug: FMX103 minocycline foam 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study: NCT00370136
Drug: ultrasound contrast
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00337194
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03631121
Drug: Basalin to Lantus
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
Study: NCT02018887
Drug: LY2969822
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT02018887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT00005940
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005940
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02920567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
Study: NCT00499538
Drug: SKI-606
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02491060
Drug: IDP-121 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: IDP-121 Lotion
Study: NCT02491060
Drug: IDP-121 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Product: IDP-121 Vehicle Lotion
Study: NCT00201773
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
Study: NCT00708006
Drug: HGS1029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
Study: NCT00281580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Telmisartan and Amlodipine once daily for eight weeks
Study: NCT00404300
Drug: Optivate
Normalized name: Optivate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived Factor VIII
Study: NCT01694186
Drug: FAI insert
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005684
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00926705
Drug: Dexmedetomidine and Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
Study: NCT00926705
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
Study: NCT00671502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT03725059
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline or dextrose IV infusion Q3W
Study: NCT03725059
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion either in Q2W or Q3W
Study: NCT03725059
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion either in Q2W or Q3W
Study: NCT03725059
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable endocrine therapy for up 10 years
Study: NCT01168531
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin B complex formula
Study: NCT00191152
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
Study: NCT02358395
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered continuously twice daily with doses separated by 9-15 hours.
Study: NCT00445120
Drug: Lactobacillus Rhamnosus GG
Normalized name: Lactobacillus rhamnosus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
Study: NCT00445120
Drug: placebo (sugar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to patients once daily for six months
Study: NCT00047268
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01935154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00976300
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Study: NCT00083109
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03193307
Drug: Microgynon® 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run in period \& Treatment Period
Study: NCT00502515
Drug: SSR180575
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily dosing
Study: NCT00502515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily dosing
Study: NCT02846428
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study: NCT02846428
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study: NCT02273466
Drug: Desipramine tablet
Normalized name: desipramine Oral Tablet
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02273466
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00881244
Drug: AS1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.v. 4-7 days, 1-40 mg/kg/day
Study: NCT03093168
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 40mg/kg
Study: NCT00986895
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
Study: NCT02644811
Drug: Topical anesthesia (buccal and palatal)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
Study: NCT02644811
Drug: Topical anesthesia (buccal)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
Study: NCT02509299
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study: NCT04536532
Drug: HEC121120 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT02268851
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken whole daily with water and with food
Study: NCT02370693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
Study: NCT02922660
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
Study: NCT03599466
Drug: Zestril Tab 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zestril Tab 20mg will be used as a reference drug in this study
Study: NCT01864096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.